MovDisordV3, PascalFrancis, Curation, bibRecord, 000141

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake

Identifieur interne : 000141 ( PascalFrancis/Curation ); précédent : 000140; suivant : 000142

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake

Auteurs : H. T. S. Benamer [Royaume-Uni] ; J. Patterson [Royaume-Uni] ; D. J. Wyper [Royaume-Uni] ; D. M. Hadley [Royaume-Uni] ; G. J. A. Macphee [Royaume-Uni] ; D. G. Grosset [Royaume-Uni]

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:00-0396265

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Tomoscintigraphie, Photon, Corps strié, Transmission dopaminergique, Exploration, Pronostic, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Corpus striatum, Dopaminergic transmission, Emission tomography, Exploration, Human, Parkinson disease, Photon, Prognosis.

Abstract

The variability in clinical features and the masking effects of drug therapy in Parkinson's disease (PD) can affect clinical assessment of disease severity. The aim of this study was to assess the imaging of dopamine transporters using ¹²³I-FP-CIT SPECT and its correlation with disease staging, severity, and duration. Differences between the clinical severity of the onset and non-onset side and the corresponding striatal uptake ratios were also examined. Forty-one patients with PD (nine unilateral, 32 bilateral clinical features) were studied. Clinical severity was determined by using the Unified Parkinson's Disease Rating Score (UPDRS). Unilateral UPDRS was calculated from unilateral arm and leg resting and action tremor, rigidity, finger taps, hand movements, alternating movements, and leg agility. ¹²³I-FP-CIT striatal uptake was expressed as the ratio of specific:nonspecific (SP:NS) uptake for defined brain areas. Patients with PD who had unilateral symptoms showed a significant difference between the ipsilateral and contralateral SP:NS ratios in both the caudate and putamen, but there was a considerable overlap between between the two sides. This result was repeated in patients with bilateral symptoms and there was overlap of SP:NS ratios between the two groups. For the whole group of patients with PD, striatum, caudate, and putamen SP:NS ratios correlated with disease severity assessed by UPDRS and duration of disease, The SP:NS ratios correlated with the bradykinesia subscore but not with rigidity or tremor subscore. In conclusion, this study provides further evidence that the SP:NS ratio is a robust measure of disease severity correlating with duration of PD. However, variability in uptake values suggest that factors other than nigrostriatal degeneration may contribute to disease severity. Correlation with bradykinesia but not with tremor may indicate an origin for tremor outwith the dopamine transporter system. ¹²³I-FP-CIT SPECT offers significant potential in defining the nigrostriatal changes in PD.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Correlation of Parkinson's disease severity and duration with ¹²³I-FP-CIT SPECT striatal uptake`
A11	`01`	`1`		`@1 BENAMER (H. T. S.)`
A11	`02`	`1`		`@1 PATTERSON (J.)`
A11	`03`	`1`		`@1 WYPER (D. J.)`
A11	`04`	`1`		`@1 HADLEY (D. M.)`
A11	`05`	`1`		`@1 MACPHEE (G. J. A.)`
A11	`06`	`1`		`@1 GROSSET (D. G.)`
A14	`01`			`@1 Institute of Neurological Sciences Glasgow @3 GBR @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 692-698`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000090295630140`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 38 ref.`
A47	`01`	`1`		`@0 00-0396265`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The variability in clinical features and the masking effects of drug therapy in Parkinson's disease (PD) can affect clinical assessment of disease severity. The aim of this study was to assess the imaging of dopamine transporters using ¹²³I-FP-CIT SPECT and its correlation with disease staging, severity, and duration. Differences between the clinical severity of the onset and non-onset side and the corresponding striatal uptake ratios were also examined. Forty-one patients with PD (nine unilateral, 32 bilateral clinical features) were studied. Clinical severity was determined by using the Unified Parkinson's Disease Rating Score (UPDRS). Unilateral UPDRS was calculated from unilateral arm and leg resting and action tremor, rigidity, finger taps, hand movements, alternating movements, and leg agility. ¹²³I-FP-CIT striatal uptake was expressed as the ratio of specific:nonspecific (SP:NS) uptake for defined brain areas. Patients with PD who had unilateral symptoms showed a significant difference between the ipsilateral and contralateral SP:NS ratios in both the caudate and putamen, but there was a considerable overlap between between the two sides. This result was repeated in patients with bilateral symptoms and there was overlap of SP:NS ratios between the two groups. For the whole group of patients with PD, striatum, caudate, and putamen SP:NS ratios correlated with disease severity assessed by UPDRS and duration of disease, The SP:NS ratios correlated with the bradykinesia subscore but not with rigidity or tremor subscore. In conclusion, this study provides further evidence that the SP:NS ratio is a robust measure of disease severity correlating with duration of PD. However, variability in uptake values suggest that factors other than nigrostriatal degeneration may contribute to disease severity. Correlation with bradykinesia but not with tremor may indicate an origin for tremor outwith the dopamine transporter system. ¹²³I-FP-CIT SPECT offers significant potential in defining the nigrostriatal changes in PD.
C02	`01`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Tomoscintigraphie @5 04`
C03	`02`	`X`	`ENG`	`@0 Emission tomography @5 04`
C03	`02`	`X`	`SPA`	`@0 Tomocentelleografía @5 04`
C03	`03`	`X`	`FRE`	`@0 Photon @5 05`
C03	`03`	`X`	`ENG`	`@0 Photon @5 05`
C03	`03`	`X`	`SPA`	`@0 Fotón @5 05`
C03	`04`	`X`	`FRE`	`@0 Corps strié @5 07`
C03	`04`	`X`	`ENG`	`@0 Corpus striatum @5 07`
C03	`04`	`X`	`SPA`	`@0 Cuerpo estriado @5 07`
C03	`05`	`X`	`FRE`	`@0 Transmission dopaminergique @5 10`
C03	`05`	`X`	`ENG`	`@0 Dopaminergic transmission @5 10`
C03	`05`	`X`	`SPA`	`@0 Transmisión dopaminérgica @5 10`
C03	`06`	`X`	`FRE`	`@0 Exploration @5 17`
C03	`06`	`X`	`ENG`	`@0 Exploration @5 17`
C03	`06`	`X`	`SPA`	`@0 Exploración @5 17`
C03	`07`	`X`	`FRE`	`@0 Pronostic @5 18`
C03	`07`	`X`	`ENG`	`@0 Prognosis @5 18`
C03	`07`	`X`	`SPA`	`@0 Pronóstico @5 18`
C03	`08`	`X`	`FRE`	`@0 Homme @5 20`
C03	`08`	`X`	`ENG`	`@0 Human @5 20`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Exploration radioisotopique @5 45`
C07	`06`	`X`	`ENG`	`@0 Radionuclide study @5 45`
C07	`06`	`X`	`SPA`	`@0 Exploración radioisotópica @5 45`
C07	`07`	`X`	`FRE`	`@0 Encéphale @5 53`
C07	`07`	`X`	`ENG`	`@0 Brain (vertebrata) @5 53`
C07	`07`	`X`	`SPA`	`@0 Encéfalo @5 53`
N21				`@1 269`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B80

Links to Exploration step

Pascal:00-0396265

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Correlation of Parkinson's disease severity and duration with <sup>123</sup>
I-FP-CIT SPECT striatal uptake</title>
<author><name sortKey="Benamer, H T S" sort="Benamer, H T S" uniqKey="Benamer H" first="H. T. S." last="Benamer">H. T. S. Benamer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Patterson, J" sort="Patterson, J" uniqKey="Patterson J" first="J." last="Patterson">J. Patterson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Wyper, D J" sort="Wyper, D J" uniqKey="Wyper D" first="D. J." last="Wyper">D. J. Wyper</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Hadley, D M" sort="Hadley, D M" uniqKey="Hadley D" first="D. M." last="Hadley">D. M. Hadley</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Macphee, G J A" sort="Macphee, G J A" uniqKey="Macphee G" first="G. J. A." last="Macphee">G. J. A. Macphee</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Grosset, D G" sort="Grosset, D G" uniqKey="Grosset D" first="D. G." last="Grosset">D. G. Grosset</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0396265</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0396265 INIST</idno>
<idno type="RBID">Pascal:00-0396265</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B80</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000141</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Correlation of Parkinson's disease severity and duration with <sup>123</sup>
I-FP-CIT SPECT striatal uptake</title>
<author><name sortKey="Benamer, H T S" sort="Benamer, H T S" uniqKey="Benamer H" first="H. T. S." last="Benamer">H. T. S. Benamer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Patterson, J" sort="Patterson, J" uniqKey="Patterson J" first="J." last="Patterson">J. Patterson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Wyper, D J" sort="Wyper, D J" uniqKey="Wyper D" first="D. J." last="Wyper">D. J. Wyper</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Hadley, D M" sort="Hadley, D M" uniqKey="Hadley D" first="D. M." last="Hadley">D. M. Hadley</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Macphee, G J A" sort="Macphee, G J A" uniqKey="Macphee G" first="G. J. A." last="Macphee">G. J. A. Macphee</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Grosset, D G" sort="Grosset, D G" uniqKey="Grosset D" first="D. G." last="Grosset">D. G. Grosset</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Corpus striatum</term>
<term>Dopaminergic transmission</term>
<term>Emission tomography</term>
<term>Exploration</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Photon</term>
<term>Prognosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Tomoscintigraphie</term>
<term>Photon</term>
<term>Corps strié</term>
<term>Transmission dopaminergique</term>
<term>Exploration</term>
<term>Pronostic</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The variability in clinical features and the masking effects of drug therapy in Parkinson's disease (PD) can affect clinical assessment of disease severity. The aim of this study was to assess the imaging of dopamine transporters using <sup>123</sup>
I-FP-CIT SPECT and its correlation with disease staging, severity, and duration. Differences between the clinical severity of the onset and non-onset side and the corresponding striatal uptake ratios were also examined. Forty-one patients with PD (nine unilateral, 32 bilateral clinical features) were studied. Clinical severity was determined by using the Unified Parkinson's Disease Rating Score (UPDRS). Unilateral UPDRS was calculated from unilateral arm and leg resting and action tremor, rigidity, finger taps, hand movements, alternating movements, and leg agility. <sup>123</sup>
I-FP-CIT striatal uptake was expressed as the ratio of specific:nonspecific (SP:NS) uptake for defined brain areas. Patients with PD who had unilateral symptoms showed a significant difference between the ipsilateral and contralateral SP:NS ratios in both the caudate and putamen, but there was a considerable overlap between between the two sides. This result was repeated in patients with bilateral symptoms and there was overlap of SP:NS ratios between the two groups. For the whole group of patients with PD, striatum, caudate, and putamen SP:NS ratios correlated with disease severity assessed by UPDRS and duration of disease, The SP:NS ratios correlated with the bradykinesia subscore but not with rigidity or tremor subscore. In conclusion, this study provides further evidence that the SP:NS ratio is a robust measure of disease severity correlating with duration of PD. However, variability in uptake values suggest that factors other than nigrostriatal degeneration may contribute to disease severity. Correlation with bradykinesia but not with tremor may indicate an origin for tremor outwith the dopamine transporter system. <sup>123</sup>
I-FP-CIT SPECT offers significant potential in defining the nigrostriatal changes in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Correlation of Parkinson's disease severity and duration with <sup>123</sup>
I-FP-CIT SPECT striatal uptake</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BENAMER (H. T. S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PATTERSON (J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>WYPER (D. J.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HADLEY (D. M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MACPHEE (G. J. A.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GROSSET (D. G.)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Neurological Sciences Glasgow</s1>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>692-698</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000090295630140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>38 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0396265</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The variability in clinical features and the masking effects of drug therapy in Parkinson's disease (PD) can affect clinical assessment of disease severity. The aim of this study was to assess the imaging of dopamine transporters using <sup>123</sup>
I-FP-CIT SPECT and its correlation with disease staging, severity, and duration. Differences between the clinical severity of the onset and non-onset side and the corresponding striatal uptake ratios were also examined. Forty-one patients with PD (nine unilateral, 32 bilateral clinical features) were studied. Clinical severity was determined by using the Unified Parkinson's Disease Rating Score (UPDRS). Unilateral UPDRS was calculated from unilateral arm and leg resting and action tremor, rigidity, finger taps, hand movements, alternating movements, and leg agility. <sup>123</sup>
I-FP-CIT striatal uptake was expressed as the ratio of specific:nonspecific (SP:NS) uptake for defined brain areas. Patients with PD who had unilateral symptoms showed a significant difference between the ipsilateral and contralateral SP:NS ratios in both the caudate and putamen, but there was a considerable overlap between between the two sides. This result was repeated in patients with bilateral symptoms and there was overlap of SP:NS ratios between the two groups. For the whole group of patients with PD, striatum, caudate, and putamen SP:NS ratios correlated with disease severity assessed by UPDRS and duration of disease, The SP:NS ratios correlated with the bradykinesia subscore but not with rigidity or tremor subscore. In conclusion, this study provides further evidence that the SP:NS ratio is a robust measure of disease severity correlating with duration of PD. However, variability in uptake values suggest that factors other than nigrostriatal degeneration may contribute to disease severity. Correlation with bradykinesia but not with tremor may indicate an origin for tremor outwith the dopamine transporter system. <sup>123</sup>
I-FP-CIT SPECT offers significant potential in defining the nigrostriatal changes in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Photon</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Photon</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Fotón</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Corps strié</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Corpus striatum</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Cuerpo estriado</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Transmission dopaminergique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopaminergic transmission</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Transmisión dopaminérgica</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Exploration</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Exploration</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Exploración</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>18</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Exploration radioisotopique</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Radionuclide study</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Exploración radioisotópica</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Brain (vertebrata)</s0>
<s5>53</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo</s0>
<s5>53</s5>
</fC07>
<fN21><s1>269</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000141 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000141 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:00-0396265
   |texte=   Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri